<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00531336</url>
  </required_header>
  <id_info>
    <org_study_id>EK06-001839-18</org_study_id>
    <nct_id>NCT00531336</nct_id>
  </id_info>
  <brief_title>MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen</brief_title>
  <official_title>Comparison of Combined Therapy of Intravitreal Injection of Avastin and Macugen Versus Mono-Therapy The MAAM Study - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first results of Anti-Vascular Endothelial Growth Factor (VEGF) therapy were very&#xD;
      promising and superior to established therapies. Three different substances (all of them&#xD;
      applied intravitreally) are available, but comparative studies have not yet been conducted.&#xD;
      In this pilot study, the safety (number of adverse events) and efficacy (distance acuity&#xD;
      testing retinal thickness measurement) of Avastin and Macugen applied as monotherapy will be&#xD;
      compared to a combined treatment of Avastin followed by Macugen used for retreatment.&#xD;
&#xD;
      At least equal results of the combined therapy are expected.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The role of Vascular Endothelial Growth Factor (VEGF) in the pathogenesis of neovascular&#xD;
      diseases like choroidal neovascularization (CNV) and proliferative diabetic retinopathy has&#xD;
      been demonstrated in a series of publications. Therefore intravitreally applied VEGF&#xD;
      antagonists have been used in the treatment of CNV in age-related macular degeneration (AMD)&#xD;
      and diabetic cases. Three anti-VEGFs are available: Macugen® (Pegaptanib), Avastin®&#xD;
      (Bevacizumab) and Lucentis® (Ranibizmab). Pegaptanib sodium is an aptamer designed to bind&#xD;
      the VEGF 165 isoform with high affinity. Bevacizumab is a humanized monoclonal antibody to&#xD;
      VEGF designed for intravenous administration and approved for the treatment of colorectal&#xD;
      cancer. Ranibizumab is an anti-body binding site fragment that is derived from the same&#xD;
      anti-VEGF antibody as bevacizumab. The decrease of retinal thickness measured in the OCT&#xD;
      provides information concerning the amount of intraretinal fluid accumulation and therefore&#xD;
      for the activity of a neovascular lesion. It has been proven that the aqueous humor levels of&#xD;
      VEGF of eyes with CNV are significantly higher than those of eyes without ocular or systemic&#xD;
      diseases. The retinal thickness and the VEGF concentration in the aqueous humor should give a&#xD;
      good correlation to the anti vasogenic effect of the intravitreal treatment. In this study&#xD;
      bevacizumab and pegaptanib as monotherapy should be compared with a combined therapy of&#xD;
      bevacizumab applied first with pegaptanib used for retreatment. The benefit of this combined&#xD;
      therapy should be that an initial blockage of all VEGF isoforms is necessary whereas for&#xD;
      retreatment the blockage of the most important isoform in the pathogenesis of CNV is&#xD;
      sufficient and the normal function of the retinal pigment epithelium and the choriocapillaris&#xD;
      is not affected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>retinal thickness</measure>
    <time_frame>54 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>distance acuity</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of adverse events</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avastin first followed by retreatment of Macugen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Avastin intravitreally every 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Macugen intravitreally every 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal injection of Bevacizumab (Avastin)</intervention_name>
    <description>1.25 mg Avastin intravitreally applied once in arm 1 every 6 weeks in arm 2</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaptanib (Macugen)</intervention_name>
    <description>0.3 mg intravitreally applied every 6 weeks as long as required</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 50 years&#xD;
&#xD;
          -  Predominantly occult CNV&#xD;
&#xD;
          -  Greatest diameter of the lesion &lt; 5400µm&#xD;
&#xD;
          -  Distance acuity &gt; 0.1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Complicating general disorders inflicting with healing process&#xD;
&#xD;
          -  Vision threatening diseases other than CNV&#xD;
&#xD;
          -  Prior treatment for CNV&#xD;
&#xD;
          -  Ophthalmic surgery within 4 weeks&#xD;
&#xD;
          -  Not consented patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilse Krebs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig Boltzmann Institute for Biomicroscopic Lasersurgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery</name>
      <address>
        <city>Vienna</city>
        <zip>A1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>September 15, 2007</study_first_submitted>
  <study_first_submitted_qc>September 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2007</study_first_posted>
  <last_update_submitted>June 30, 2009</last_update_submitted>
  <last_update_submitted_qc>June 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Susanne Binder Prof</name_title>
    <organization>The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery</organization>
  </responsible_party>
  <keyword>age-related Macular degeneration</keyword>
  <keyword>Macugen</keyword>
  <keyword>Avastin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

